MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.53
+0.08
+1.24%
After Hours: 6.53 0 0.00% 16:41 05/16 EDT
OPEN
6.41
PREV CLOSE
6.45
HIGH
6.85
LOW
6.28
VOLUME
287.23K
TURNOVER
0
52 WEEK HIGH
10.60
52 WEEK LOW
2.460
MARKET CAP
251.12M
P/E (TTM)
-3.4806
1D
5D
1M
3M
1Y
5Y
BRIEF-Voyager Therapeutics To Present Preclinical Data From Its Vectorized Anti-Her2 Antibody Program
reuters.com · 12h ago
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid improved transduction in multiple CNS regions and cell type...
GlobeNewswire · 13h ago
--Wedbush Cuts Price Target on Voyager Therapeutics to $3 From $4 on 'Lower Net Cash,' Maintains Neutral Rating
MT Newswires · 05/05 05:05
Voyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01M
Voyager Therapeutics press release (NASDAQ:VYGR): Q1 GAAP EPS of -$0.56. Revenue of $0.7M (-89.2% Y/Y) misses by $12.01M. Cash, cash equivalents and marketable debt securities as of March 31, 2022
Seekingalpha · 05/04 21:38
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 21:35
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Zacks · 05/04 17:22
-- Earnings Flash (VYGR) VOYAGER THERAPEUTICS Posts Q1 Loss $-0.56
MT Newswires · 05/04 16:17
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at th...
GlobeNewswire · 05/03 11:00
More
No Data
Learn about the latest financial forecast of VYGR. Analyze the recent business situations of Voyager Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
12.50%Buy
62.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VYGR stock price target is 6.60 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average6.60
Low3.000
Current 6.53
EPS
Actual
Estimate
-0.60-0.41-0.21-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 132
Institutional Holdings: 22.23M
% Owned: 57.80%
Shares Outstanding: 38.46M
TypeInstitutionsShares
Increased
11
3.52M
New
13
857.29K
Decreased
22
3.05M
Sold Out
24
5.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Michael Higgins
President/Chief Executive Officer/Director
Alfred Sandrock
Chief Operating Officer
Robin Swartz
Senior Vice President/General Counsel
Robert Hesslein
Chief Scientific Officer/Director
Glenn Pierce
Vice President - Finance
Julie Burek
Director
Steven Paul
Independent Director
James Geraghty
Independent Director
Steven Hyman
Independent Director
Mark Levin
Independent Director
Nancy Vitale
No Data
No Data
About VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company that is focused on developing treatments for patients suffering from severe neurological diseases. The Company's pipeline consists of programs for severe neurological indications, including Huntington’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); and tau-related diseases including Alzheimer’s disease, frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Its pipeline is also focused on advancing gene therapies that leverage AAV capsids (TRACER) and vectorized antibodies. It is focused on identifying AAV capsids, which are the outer viral protein shells that enclose the genetic material of the virus payload. The Company is developing vectorized antibodies, including vectorized antibody compounds, which consist of a virus vector genome that encodes approximately one or more antibodies that target and bind to a tau protein.

Webull offers kinds of Voyager Therapeutics Inc stock information, including NASDAQ:VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.